These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 23571171)

  • 1. Is there any room for therapeutic vaccination against the HIV-1/AIDS?
    Iglesias E
    Hum Vaccin Immunother; 2013 Jul; 9(7):1539-44. PubMed ID: 23571171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Th2-Th1 shift with the multiantigenic formulation TERAVAC-HIV-1 in Balb/c mice.
    García-Díaz D; Rodríguez I; Santisteban Y; Márquez G; Terrero Y; Brown E; Iglesias E
    Immunol Lett; 2013 Jan; 149(1-2):77-84. PubMed ID: 23183092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of Th1/Th2 immune responses to HIV-1 Tat by new pro-GSH molecules.
    Fraternale A; Paoletti MF; Dominici S; Buondelmonte C; Caputo A; Castaldello A; Tripiciano A; Cafaro A; Palamara AT; Sgarbanti R; Garaci E; Ensoli B; Magnani M
    Vaccine; 2011 Sep; 29(40):6823-9. PubMed ID: 21816192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic vaccination against HIV: current progress and future possibilities.
    Puls RL; Emery S
    Clin Sci (Lond); 2006 Jan; 110(1):59-71. PubMed ID: 16336205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [HIV vaccine: how far along are we?].
    Reiss EIMM; van Gils MJ; Sanders RW; de Bree GJ
    Ned Tijdschr Geneeskd; 2020 Sep; 164():. PubMed ID: 33030332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of prophylactic AIDS vaccines: the current state of affairs.
    Hanke T
    Curr Opin Mol Ther; 2003 Feb; 5(1):25-32. PubMed ID: 12669467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic vaccination for future management of HIV/AIDS.
    Lisziewicz J; Bakare N; Lori F
    Vaccine; 2003 Jan; 21(7-8):620-3. PubMed ID: 12531329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects for vaccine protection against HIV-1 infection and AIDS.
    Letvin NL; Barouch DH; Montefiori DC
    Annu Rev Immunol; 2002; 20():73-99. PubMed ID: 11861598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1/AIDS vaccine development: are we in the darkness.
    Qiu C; Xu JQ
    Chin Med J (Engl); 2008 May; 121(10):939-45. PubMed ID: 18706210
    [No Abstract]   [Full Text] [Related]  

  • 10. HIV vaccine: hopes and hurdles.
    Chhatbar C; Mishra R; Kumar A; Singh SK
    Drug Discov Today; 2011 Nov; 16(21-22):948-56. PubMed ID: 21889604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thorny issues in the ethics of AIDS vaccine trials.
    Berkley S
    Lancet; 2003 Sep; 362(9388):992. PubMed ID: 14513850
    [No Abstract]   [Full Text] [Related]  

  • 12. HIV-1 matrix protein p17: a candidate antigen for therapeutic vaccines against AIDS.
    Fiorentini S; Giagulli C; Caccuri F; Magiera AK; Caruso A
    Pharmacol Ther; 2010 Dec; 128(3):433-44. PubMed ID: 20816696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term persistence of vaccination and HAART to human immunodeficiency virus (HIV).
    Boström AC; Hejdeman B; Matsuda R; Fredriksson M; Fredriksson EL; Bratt G; Sandström E; Wahren B
    Vaccine; 2004 Apr; 22(13-14):1683-91. PubMed ID: 15068851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartments.
    Hone DM; DeVico AL; Fouts TR; Onyabe DY; Agwale SM; Wambebe CO; Blattner WA; Gallo RC; Lewis GK
    J Hum Virol; 2002; 5(1):17-23. PubMed ID: 12352264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.
    Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C
    J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic immunization strategies for the control of HIV-1.
    Dorrell L
    Expert Rev Vaccines; 2005 Aug; 4(4):513-20. PubMed ID: 16117708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [HIV/AIDS vaccines: heading for new vaccine approaches?].
    Girard MP
    Bull Soc Pathol Exot; 2008 Jun; 101(3):220-6. PubMed ID: 18681215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential pitfalls on the road to an effective HIV vaccine.
    Schwartz DH
    Immunol Today; 1994 Feb; 15(2):54-7. PubMed ID: 7908803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV immunotherapy comes of age: implications for prevention, treatment and cure.
    Routy JP; Mehraj V; Cao W
    Expert Rev Clin Immunol; 2016; 12(2):91-4. PubMed ID: 26629806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection.
    Fanales-Belasio E; Moretti S; Fiorelli V; Tripiciano A; Pavone Cossut MR; Scoglio A; Collacchi B; Nappi F; Macchia I; Bellino S; Francavilla V; Caputo A; Barillari G; Magnani M; Laguardia ME; Cafaro A; Titti F; Monini P; Ensoli F; Ensoli B
    J Immunol; 2009 Mar; 182(5):2888-97. PubMed ID: 19234184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.